Tags

Type your tag names separated by a space and hit enter

Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis.
Dermatology. 2009; 219(3):239-49.D

Abstract

OBJECTIVE

To assess baseline patient-reported outcomes (PROs) and PRO improvement in patients with psoriasis administered etanercept 50 mg once weekly (QW).

METHODS

Adult patients with moderate-to-severe plaque psoriasis participated in a 12-week, double-blind, controlled trial in which they received etanercept 50 mg QW (n = 96) or placebo QW (n = 46), followed by a 12-week, open-label extension in which they received etanercept 50 mg QW (etanercept-etanercept, n = 90; placebo-etanercept, n = 36). Patients completed the Dermatology Life Quality Index (DLQI), EuroQoL-5D (EQ-5D) and Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) at baseline and subsequent study visits.

RESULTS

At baseline, DLQI and EQ-5D scores indicated significant quality of life (QoL) impairment, and FACIT-F scores suggested more fatigue than in the general population. At week 12, etanercept 50 mg QW provided statistically significantly (p < 0.05) and clinically meaningfully greater improvement in DLQI and EQ-5D utility scores than placebo, but not in FACIT-F scores. After 24 weeks of etanercept, the mean DLQI suggested psoriasis had a small effect on QoL, while EQ-5D and FACIT-F scores were comparable to population norms.

CONCLUSIONS

Patients with moderate-to-severe psoriasis entered this trial with serious PRO impairment. At week 12, etanercept 50 mg QW provided significant QoL improvements compared with placebo. After 24 weeks of etanercept, the patients' serious PRO impairment had largely abated.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Reich K
Dermatologikum, Hamburg, Germany. kreich@dermatologikum.de
Segaert S
No affiliation info available
Van de Kerkhof P
No affiliation info available
Durian C
No affiliation info available
Boussuge MP
No affiliation info available
Paolozzi L
No affiliation info available
Wajdula J
No affiliation info available
Boggs R
No affiliation info available

MeSH

AdultDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleEtanerceptFemaleFollow-Up StudiesHumansImmunoglobulin GImmunosuppressive AgentsInjections, SubcutaneousMaleMiddle AgedPatient SatisfactionPsoriasisQuality of LifeReceptors, Tumor Necrosis FactorSeverity of Illness IndexTime FactorsTreatment OutcomeTumor Necrosis Factor-alpha

Pub Type(s)

Clinical Trial, Phase I
Clinical Trial, Phase II
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19752505

Citation

Reich, Kristian, et al. "Once-weekly Administration of Etanercept 50 Mg Improves Patient-reported Outcomes in Patients With Moderate-to-severe Plaque Psoriasis." Dermatology (Basel, Switzerland), vol. 219, no. 3, 2009, pp. 239-49.
Reich K, Segaert S, Van de Kerkhof P, et al. Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis. Dermatology. 2009;219(3):239-49.
Reich, K., Segaert, S., Van de Kerkhof, P., Durian, C., Boussuge, M. P., Paolozzi, L., Wajdula, J., & Boggs, R. (2009). Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis. Dermatology (Basel, Switzerland), 219(3), 239-49. https://doi.org/10.1159/000237871
Reich K, et al. Once-weekly Administration of Etanercept 50 Mg Improves Patient-reported Outcomes in Patients With Moderate-to-severe Plaque Psoriasis. Dermatology. 2009;219(3):239-49. PubMed PMID: 19752505.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis. AU - Reich,Kristian, AU - Segaert,Siegfried, AU - Van de Kerkhof,Peter, AU - Durian,Cis, AU - Boussuge,Marie Pierre, AU - Paolozzi,Laurence, AU - Wajdula,Joseph, AU - Boggs,Robert, Y1 - 2009/09/10/ PY - 2009/02/18/received PY - 2009/05/26/accepted PY - 2009/9/16/entrez PY - 2009/9/16/pubmed PY - 2010/1/20/medline SP - 239 EP - 49 JF - Dermatology (Basel, Switzerland) JO - Dermatology VL - 219 IS - 3 N2 - OBJECTIVE: To assess baseline patient-reported outcomes (PROs) and PRO improvement in patients with psoriasis administered etanercept 50 mg once weekly (QW). METHODS: Adult patients with moderate-to-severe plaque psoriasis participated in a 12-week, double-blind, controlled trial in which they received etanercept 50 mg QW (n = 96) or placebo QW (n = 46), followed by a 12-week, open-label extension in which they received etanercept 50 mg QW (etanercept-etanercept, n = 90; placebo-etanercept, n = 36). Patients completed the Dermatology Life Quality Index (DLQI), EuroQoL-5D (EQ-5D) and Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) at baseline and subsequent study visits. RESULTS: At baseline, DLQI and EQ-5D scores indicated significant quality of life (QoL) impairment, and FACIT-F scores suggested more fatigue than in the general population. At week 12, etanercept 50 mg QW provided statistically significantly (p < 0.05) and clinically meaningfully greater improvement in DLQI and EQ-5D utility scores than placebo, but not in FACIT-F scores. After 24 weeks of etanercept, the mean DLQI suggested psoriasis had a small effect on QoL, while EQ-5D and FACIT-F scores were comparable to population norms. CONCLUSIONS: Patients with moderate-to-severe psoriasis entered this trial with serious PRO impairment. At week 12, etanercept 50 mg QW provided significant QoL improvements compared with placebo. After 24 weeks of etanercept, the patients' serious PRO impairment had largely abated. SN - 1421-9832 UR - https://www.unboundmedicine.com/medline/citation/19752505/Once_weekly_administration_of_etanercept_50_mg_improves_patient_reported_outcomes_in_patients_with_moderate_to_severe_plaque_psoriasis_ DB - PRIME DP - Unbound Medicine ER -